var data={"title":"Vinblastine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Vinblastine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7151?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=vinblastine-drug-information\" class=\"drug drug_general\">see &quot;Vinblastine: Drug information&quot;</a> and <a href=\"topic.htm?path=vinblastine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Vinblastine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708853\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">This preparation should be administered by individuals experienced in the administration of vinblastine sulfate. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Extravasation: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\"> It is extremely important that the intravenous needle or catheter be properly positioned before any vinblastine sulfate is injected. Leakage into surrounding tissue during intravenous administration of vinblastine may cause considerable irritation. If extravasation occurs, the injection should be discontinued immediately, and any remaining portion of the dose should then be introduced into another vein. Local injection of hyaluronidase and the application of moderate heat to the area of leakage help disperse the drug and are thought to minimize discomfort and the possibility of cellulitis.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate administration:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">For intravenous use only - fatal if given by other routes.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369039\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Vinblastine Sulphate Injection</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050585\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimicrotubular</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Mitotic Inhibitor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Vinca Alkaloid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050577\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=vinblastine-drug-information\" class=\"drug drug_general\">see &quot;Vinblastine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Dosing and frequency may vary by indication, protocol, and/or treatment phase and hematologic response; refer to specific protocol. <b>For IV use only.</b> In order to prevent inadvertent intrathecal administration, the Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag (<b>NOT</b> a syringe).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin lymphoma:</b> Infants, Children, and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Initial dose: 6 mg/m<sup>2</sup>/dose; do not administer more frequently than every 7 days</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ABVD regimen: 6 mg/m<sup>2</sup>/dose administered on days 1 and 15 of a 28 day cycle in combination with doxorubicin, bleomycin, and darcarbazine (Hutchinson, 1989) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ChlVPP regimen: 6 mg/m<sup>2</sup>/dose administered on days 1 and 8 of a 28 day cycle in combination with chlorambucil, procarbazine, and prednisolone; minimum reported age: 7 months (Atra, 2002; Capra, 2007; Hall, 2007; Stoneham, 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\"> <b>Langerhans cell histiocytosis; multisystem (Letterer-Siwe disease; Histiocytosis X):</b> Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: Initial dose: 6.5 mg/m<sup>2</sup>/dose; do not administer more frequently than every 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Limited data available: Induction: 6 mg/m<sup>2</sup>/dose every 7 days in combination with prednisone for 6 to 12 weeks \tdepending upon clinical response; then begin maintenance therapy of 6 mg/m<sup>2</sup>/dose every 3 weeks in combination with prednisone, continue for a total duration of vinblastine therapy of 12 months (Gadner, 2013; Haupt, 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Germ cell tumors; extracranial (eg, testicular, ovarian, mediastinal):</b> Infants, Children, and Adolescents: IV: Initial dose: 3 mg/m<sup>2</sup>/dose; per the manufacturer, do not administer more frequently than every 7 days; however, in some trials, a single dose was used (Lopes, 2009) and others used a daily dose of vinblastine administered over 1 hour for 2 days (G&ouml;bel, 2001; Schneider, 2000)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Hodgkin lymphoma, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides, testicular cancer, Kaposi sarcoma, histiocytosis X (Letterer-Siwe disease): </b> IV: Initial: 3.7 mg/m<sup>2</sup>; adjust dose every 7 days (based on white blood cell response) up to 5.5 mg/m<sup>2</sup> (second dose); 7.4 mg/m<sup>2</sup> (third dose); 9.25 mg/m<sup>2</sup> (fourth dose); and 11.1 mg/m<sup>2</sup> (fifth dose); do not administer more frequently than every 7 days. Usual dosage range: 5.5 to 7.4 mg/m<sup>2</sup> every 7 days; maximum dose: 18.5 mg/m<sup>2</sup>; dosage adjustment goal is to reduce white blood cell count to ~3,000/mm<sup>3 </sup></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> All patients: The manufacturer's labeling recommends the following adjustment: Serum bilirubin &gt;3 mg/dL: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\"> The following adjustments have also been recommended (Floyd, 2006; Superfin, 2007): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum bilirubin 1.5 to 3 mg/dL or transaminases 2 to 3 times ULN: Administer 50% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Serum bilirubin &gt;3 times ULN: Avoid use.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234079\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 mg/mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg (1 ea [DSC])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234064\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050589\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b> In order to prevent inadvertent intrathecal administration, the Institute for Safe Medication Practices (ISMP) strongly recommends dispensing vinblastine in a minibag (NOT in a syringe)</b>. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV infusion: For IV administration only. <b>Fatal if given intrathecally.</b> The preferred administration is as a short infusion in a minibag. If administration via a minibag is not possible, vinblastine may also be administered undiluted (1 mg/mL) over 1 minute into a free flowing IV line to prevent venous irritation/extravasation. Prolonged administration times (&ge;30 to 60 minutes) and/or increased administration volumes may increase the risk of vein irritation and extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); initiate hyaluronidase antidote (see Management of Drug Extravasations for more details); remove needle/cannula; apply dry warm compresses for 20 minutes 4 times a day for 1 to 2 days; elevate extremity (P&eacute;rez Fidalgo 2012). Remaining portion of the vinblastine dose should be infused through a separate vein.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132729\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234093\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: Vinblastine should be dispensed in a minibag (ISMP 2014). Although not recommended, if prepared in a syringe, the syringe must be dispensed in an overwrap which bears the statement &quot;Do not remove covering until the moment of injection. Fatal if given intrathecally. For IV use only.&quot; </b></p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Protect from light. Solutions diluted for infusion in NS, D5W, or LR (20 mcg/mL concentration) are stable for up to 21 days if protected from light (Beijnen 1989). The formulation of vinblastine may have changed since this stability study was conducted; consult the manufacturer&rsquo;s prescribing information for further information. Follow USP 797 recommendations for beyond use dates based on the level of risk for preparation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050588\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of Hodgkin lymphoma, lymphocytic lymphoma, histiocytic lymphoma, testicular germinal-cell cancers, Langerhans cell histiocytosis (histiocytosis X; Letterer-Siwe disease), choriocarcinoma, breast cancer (refractory/resistant), mycosis fungoides, and Kaposi&rsquo;s sarcoma (All indications: FDA approved in pediatrics [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234153\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">VinBLAStine may be confused with vinCRIStine, vinorelbine</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">For IV use only. Fatal if administered by other routes. To prevent fatal inadvertent intrathecal injection, it is strongly recommended that vinblastine doses be dispensed in a small minibag (25 to 50 mL of a compatible solution), and <b>NOT</b> a syringe (ISMP 2014). Vinblastine should <b>NOT </b>be prepared during the preparation of any intrathecal medications. After preparation, keep vinblastine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Vinblastine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234149\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, cerebrovascular accident, ECG abnormality, hypertension (common), ischemic heart disease, limb ischemia, myocardial infarction, Raynaud's phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Decreased deep tendon reflex, depression, dizziness, headache, malaise (common), metallic taste, neurotoxicity (duration: &gt;24 hours), paresthesia, peripheral neuritis, seizure, tumor pain (common), vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Alopecia (common), dermatitis, skin blister, skin photosensitivity (rare), skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperuricemia, SIADH (syndrome of inappropriate antidiuretic hormone secretion)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation (common), diarrhea, enterocolitis (hemorrhagic), gastrointestinal hemorrhage, intestinal obstruction, nausea (mild), paralytic ileus, stomatitis, toxic megacolon, vomiting (mild)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Azoospermia, urinary retention</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, bone marrow depression (common), granulocytopenia (common; nadir: 5 to 10 days; recovery: 7 to 14 days; dose-limiting toxicity), hemolytic uremic syndrome, leukopenia (common; nadir: 5 to 10 days; recovery: 7 to 14 days; dose-limiting toxicity), rectal hemorrhage, thrombocytopenia (recovery within a few days), thrombotic thrombocytopenic purpura</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Local irritation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Jaw pain (common), myalgia, ostealgia (common), weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Nystagmus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Auditory disturbance, deafness, vestibular disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, dyspnea, pharyngitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Radiation recall phenomenon</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234085\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Significant granulocytopenia (unless as a result of condition being treated); presence of bacterial infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications not in the US labeling: Pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234068\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: Leukopenia commonly occurs; granulocytopenia may be severe with higher doses. The leukocyte nadir generally occurs 5 to 10 days after administration; recovery typically occurs 7 to 14 days later. Monitor for infections if WBC &lt;2,000/mm<sup>3</sup>. Leukopenia may be more pronounced in cachectic patients and patients with skin ulceration and may be less pronounced with lower doses used for maintenance therapy. Leukocytes and platelets may fall considerably with moderate doses when marrow is infiltrated with malignant cells (further use in this situation is not recommended). Thrombocytopenia and anemia may occur rarely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: <b>[US Boxed Warning]: Vinblastine is a vesicant; ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation. Extravasation may cause significant irritation. Individuals administering should be experienced in vinblastine administration. If extravasation occurs, discontinue immediately and initiate appropriate extravasation management, including local injection of hyaluronidase and moderate heat application to the affected area. Use a separate vein to complete administration.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Stomatitis may occur (rare); may be disabling, but is usually reversible.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neurotoxicity: May rarely cause disabling neurotoxicity; usually reversible. Seizures and severe and permanent CNS damage has occurred with higher then recommended doses and/or when administered more frequently than recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary toxicity: Acute shortness of breath and severe bronchospasm have been reported, most often in association with concurrent administration of mitomycin; may occur within minutes to several hours following vinblastine administration or up to 14 days following mitomycin administration; use caution in patients with preexisting pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; toxicity may be increased; may require dosage modification.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ischemic heart disease: Use with caution in patients with ischemic heart disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hazardous agent: Avoid eye contamination (exposure may cause severe irritation).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; NOT for intrathecal use: <b>[US Boxed Warning]: For IV use only. </b><b>Intrathecal administration may result in death.</b> To prevent administration errors, the Institute for Safe Medication Practices (ISMP) Targeted Medication Safety Best Practices for Hospitals initiative strongly recommends dispensing vinblastine diluted in a minibag (ISMP 2014). <b> If not dispensed in a minibag, affix an auxiliary label stating &quot;For intravenous use only - fatal if given by other routes&quot; and also place in an overwrap labeled &quot;Do not remove covering until moment of injection.&quot;</b> Vinblastine should <b>NOT </b>be prepared during the preparation of any intrathecal medications. After preparation, keep vinblastine in a location <b>away</b> from the separate storage location recommended for intrathecal medications. Vinblastine should <b>NOT</b> be delivered to the patient at the same time with any medications intended for central nervous system administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234139\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2D6 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234073\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12881&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of ceritinib with a narrow therapeutic index CYP3A substrate (eg, alfentanil, cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus) should be avoided when possible.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Conivaptan: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: May increase the serum concentration of VinBLAStine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: May increase the serum concentration of VinBLAStine. Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of lopinavir/ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Avoid the concomitant use of posaconazole and vinca alkaloids when possible. If combined, monitor for increased vinca alkaloid toxicities (eg, neurotoxicity, gastrointestinal toxicity).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: May increase the serum concentration of VinBLAStine. Management: Monitor closely for signs and symptoms of vinblastine toxicity; consider temporary interruption of ritonavir antiviral therapy if patients develop significant toxicity with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Stiripentol: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity.  Any CYP3A4 substrate used with stiripentol requires closer monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolterodine: VinBLAStine may increase the serum concentration of Tolterodine.  Management: Reduce tolterodine dose to 1 mg twice daily (regular release formulation) or 2 mg daily (extended release formulation) (adult doses) and monitor for increased levels/effects of tolterodine with initiation of vinblastine therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234075\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6753821\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse effects were observed in animal reproduction studies. May cause fetal harm if administered during pregnancy.  Women of childbearing potential should avoid becoming pregnant during vinblastine treatment. Aspermia has been reported in males who have received treatment with vinblastine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1050584\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count, serum uric acid, hepatic function tests</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234067\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Vinblastine binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vinblastine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234084\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic (via CYP3A) to active metabolite</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: Terminal: ~25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (10%); urine (14%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16324092\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (VinBLAStine Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (10 mL): $51.68</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F234088\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Blastovin (PY);</li>\n      <li>Blastovin PF (IL);</li>\n      <li>Blestinib (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cytoblastin (BG, IN, VN);</li>\n      <li>Lemblastine (CL, CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Oncoblastin (CO, PE);</li>\n      <li>Oncostin (PH);</li>\n      <li>Velbastine (HK, KR, PH, SG);</li>\n      <li>Velbe (AE, AR, AT, AU, BE, BF, BH, BJ, CH, CI, CZ, DE, DK, EE, EG, ET, FI, FR, GB, GH, GM, GN, GR, HR, IE, IT, KE, LR, LU, MA, ML, MR, MT, MU, MW, MY, NE, NG, NL, NO, PK, PL, PT, QA, RU, SA, SC, SD, SE, SK, SL, SN, TN, TR, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Vilban (LK);</li>\n      <li>Vinatin (BR);</li>\n      <li>Vinblastin (HU, PL);</li>\n      <li>Vinblastina (CO);</li>\n      <li>Vinblastine Sulfate Injection (AU);</li>\n      <li>Xintoprost (AR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/11487763 /pubmed\" target=\"_blank\" id=\"11487763 \">11487763 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atra A, Higgs E, Capra M, et al. ChlVPP chemotherapy in children with stage IV Hodgkin's disease: results of the UKCCSG HD 8201 and HD 9201 studies. <i>Br J Haematol</i>. 2002;119(3):647-651.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/12437639 /pubmed\" target=\"_blank\" id=\"12437639 \">12437639 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balis FM, Holcenberg JS and Bleyer WA, &ldquo;Clinical Pharmacokinetics of Commonly Used Anticancer Drugs,&rdquo; <i>Clin Pharmacokinet</i>, 1983, 8(3):202-32. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/6189661/pubmed\" target=\"_blank\" id=\"6189661\">6189661</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bashir H, Motl S, Metzger ML, et al, &quot;Itraconazole-Enhanced Chemotherapy Toxicity in a Patient With Hodgkin Lymphoma,&quot; <i>J Pediatr Hematol Oncol</i>, 2006, 28(1):33-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/16394890/pubmed\" target=\"_blank\" id=\"16394890\">16394890</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capra M, Hewitt M, Radford M, et al. Long-term outcome in children with Hodgkin's lymphoma: the United Kingdom Children's Cancer Study Group HD82 trial. <i>Eur J Cancer</i>. 2007;43(7):1171-1179.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17379506 /pubmed\" target=\"_blank\" id=\"17379506 \">17379506 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Crom WR, Glynn-Barnhart AM, Rodman JH, et al, &ldquo;Pharmacokinetics of Anticancer Drugs in Children,&rdquo; <i>Clin Pharmacokinet</i>, 1987, 12(3):168-213. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/3555940/pubmed\" target=\"_blank\" id=\"3555940\">3555940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd J, Mirza I, Sachs B, Perry MC. Hepatotoxicity of chemotherapy. <i>Semin Oncol</i>. 2006;33(1):50-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/16473644 /pubmed\" target=\"_blank\" id=\"16473644 \">16473644 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. <i>Blood</i>. 2013;121(25):5006-5014<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/23589673 /pubmed\" target=\"_blank\" id=\"23589673 \">23589673 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    G&ouml;bel U, Schneider DT, Calaminus G, et al. Multimodal treatment of malignant sacrococcygeal germ cell tumors: a prospective analysis of 66 patients of the German cooperative protocols MAKEI 83/86 and 89. <i>J Clin Oncol</i>. 2001;19(7):1943-1950.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/11283126 /pubmed\" target=\"_blank\" id=\"11283126 \">11283126 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hall GW, Katzilakis N, Pinkerton CR, et al. Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma - a Children's Cancer and Leukaemia Group report. <i>Br J Haematol</i>. 2007;138(6):761-768. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17760808 /pubmed\" target=\"_blank\" id=\"17760808 \">17760808 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. <i>Pediatr Blood Cancer</i>. 2013;60(2):175-184.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/23109216 /pubmed\" target=\"_blank\" id=\"23109216 \">23109216 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hutchinson RJ, Fryer CJ, Davis PC, et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. <i>J Clin Oncol</i>. 1998;16(3):897-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/9508171 /pubmed\" target=\"_blank\" id=\"9508171 \">9508171 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices. 2014-2015 Targeted Medication Safety Best Practices for Hospitals. Available at http://www.ismp.org/tools/bestpractices/TMSBP-for-Hospitals.pdf. Accessed September 26, 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lopes LF, Macedo CR, Pontes EM, et al. Cisplatin and etoposide in childhood germ cell tumor: brazilian pediatric oncology society protocol GCT-91. <i>J Clin Oncol</i>. 2009;27(8):1297-1303.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/19164215 /pubmed\" target=\"_blank\" id=\"19164215 \">19164215 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(Suppl 7):vii167-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schneider DT, Calaminus G, Reinhard H, et al. Primary mediastinal germ cell tumors in children and adolescents: results of the German cooperative protocols MAKEI 83/86, 89, and 96. <i>J Clin Oncol</i>. 2000;18(4):832-839.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stoneham S, Ashley S, Pinkerton R, et al. Hodgkin's lymphoma in children aged 5 years or less - the United Kingdom experience. <i>Eur J Cancer</i>. 2007;43(9):1415-1421.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17509875 /pubmed\" target=\"_blank\" id=\"17509875 \">17509875 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Superfin D, Iannucci AA, Davies AM. Commentary: Oncologic drugs in patients with organ dysfunction: a summary. <i>Oncologist</i>. 2007;12(9):1070-1083.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/vinblastine-pediatric-drug-information/abstract-text/17914077 /pubmed\" target=\"_blank\" id=\"17914077 \">17914077 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12881 Version 147.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708853\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16369039\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1050585\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1050577\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F234079\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F234064\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1050589\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132729\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F234093\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1050588\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F234153\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F234149\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F234085\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F234068\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F234139\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F234073\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F234075\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F6753821\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1050584\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F234067\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F234084\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16324092\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F234088\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12881|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=vinblastine-drug-information\" class=\"drug drug_general\">Vinblastine: Drug information</a></li><li><a href=\"topic.htm?path=vinblastine-patient-drug-information\" class=\"drug drug_patient\">Vinblastine: Patient drug information</a></li></ul></div></div>","javascript":null}